STAAR Surgical Reports First Quarter 2026 Results
STAAR Surgical Company announced its first quarter 2026 financial results, reporting net sales of $93.5 million, a 119.6% increase year-over-year. Excluding sales from China, net sales were $46.1 million, up 6.0% year-over-year. The gross margin improved to 73.6% from 65.8% in the previous year, with a net income of $5.2 million, equating to $0.10 per diluted share.
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April 3, 2026. First Quarter 2026 Financial Overview Net sales of $93.5 million, up 119.6% Y/Y Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $5.2 million or $0.10 per diluted share, com